Peraldo-Neia, C.
Ostano, P.
Cavalloni, G.
Pignochino, Y.
Sangiolo, D.
De Cecco, L.
Marchesi, E.
Ribero, D.
Scarpa, A.
De Rose, A. M.
Giuliani, A.
Calise, F.
Raggi, C.
Invernizzi, P.
Aglietta, M.
Chiorino, G.
Leone, F.
Article History
Received: 20 November 2017
Accepted: 25 May 2018
First Online: 5 June 2018
Ethics approval and consent to participate
: Biological material was obtained, in accordance with the Declaration of Helsinki from patients who have signed the informed consent. The study was approved by each local institutional review boards (Comitato Etico “IRCCS Candiolo”; “Comitato Etico AORN Cardarelli-Santobono”; Comitato Etico “Policlinico Gemelli”; “Comitato Etico per la sperimentazione clinica delle province di Verona e Rovigo”; “Comitato Etico indipendente, IRCSS Istituto Clinico Humanitas”. The coordinator center approved the entire study according to the PROFILING protocol (“Studio prospettico per la determinazione del profilo molecolare di resistenza alle terapie target in pazienti con malattie neoplastiche”, 001-IRCC-00IIS-10, version 6.1, FPO-IRCCS, l’Istituto di Ricovero e Cura a Carattere Scientifico Candiolo (TO)).
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.